2019 was a year of significant progress against HIV, tuberculosis (TB), and hepatitis C virus (HCV). We shaped policy and legislation to end these conditions, secured increased funding to do so at various levels of government, and stood up for the rights of affected communities.
Treatment Action Group (TAG) joins partners, activists, and communities around the U.S. and the world in decrying violence against Black people and those who stand in solidarity with them.
Treatment Action Group (TAG) is deeply saddened to learn that the seemingly indestructible writer, activist, playwright, and agitator Larry Kramer has died at 84.
Treatment Action Group (TAG) welcomes the news that long-acting injectable cabotegravir (CAB LA, from ViiV Healthcare) demonstrated a high level of efficacy for preventing HIV infection in cisgender men and transgender women who have sex with men in the HIV Prevention Trials Network (HPTN) 083 trial.
On May 18th, TAG and 46 other organizations and individuals – including the Stop TB Partnership, Global Coalition of TB Activists, and regional networks of people living with HIV, people affected by TB, and people who use drugs – are sending this letter to authorities in the United Arab Emirates (UAE) with an urgent appeal concerning the health of people with HIV in UAE prisons who are vulnerable to COVID-19.
ICAP at Columbia, TAG, and the COVID-19 Working Group – New York presented this webinar on May 13, 2020.
The COVID-19 pandemic is a global health emergency that may demand new, safe, and expedited ways of conducting ethical research to find the solutions we need, including a safe and effective vaccine.
Realizing the Right to Science: When we started to put together this issue of TAGline, we had no idea that COVID-19 was about to make its appearance and wreak havoc on every country of the world.
Treatment Action Group (TAG) and the PrEP4All Collaboration welcome results from randomized controlled trials of therapies for COVID-19, but are seriously concerned about claims that data from a National Institutes of Allergy and Infectious Diseases (NIAID) study of the Gilead drug remdesivir...
On Friday April 24th, 2020 ANEA hosted a virtual gathering for HIV/AIDS community organizations and leaders involved in "Ending the Epidemic" state, local, or community initiatives that are experiencing disruptions from the COVID-19 pandemic.